Evidence map›Paper›PMID 40924107›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2026

Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).

Boxiang Zhang, Lucy Yue Lau, Yi Chen, Rongli Xie

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Boxiang ZhangCancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830011, China.
Lucy Yue LauDepartment of Public Health, Harvard Medical School, Boston, MA, 02115, USA.
Yi ChenCancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830011, China. chenyicsu@outlook.com.
Rongli XieDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, China. xierli@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are increasingly linked to immune-related kidney injury (irKI). This study presents the first bibliometric analysis of irKI research (2000-2025), aiming to identify key trends, mechanistic insights, and pharmacological risk factors. We analyzed 2,179 publications to understand the evolution of irKI research, focusing on areas like T cell-mediated tubular injury, immune system-driven inflammation, and changes in metabolism. Co-prescription of nonsteroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors has been identified as a pharmacological risk factor. Biomarkers such as KIM-1 and CXCL9, as well as novel imaging modalities, have shown diagnostic promise but remain underutilized. We also observed a lack of nephrotoxicity profiling for newer therapies such as chimeric antigen receptor T cell (CAR-T). This study highlights gaps in research and collaboration, particularly the need for better understanding of pharmacological risk factors like NSAID and proton pump inhibitor co-prescription. Future research should focus on improving strategies for predicting, diagnosing, and managing irKI. The study also emphasizes immune-driven inflammation, T cell-mediated tubular injury, and metabolic reprogramming as key contributors to irKI pathogenesis. Additionally, underutilized biomarkers (e.g., KIM-1, CXCL9) and emerging imaging techniques offer opportunities for early detection and monitoring.

Indexed as

Acute Kidney InjuryImmune Checkpoint InhibitorsImmunotherapyNeoplasmsAnimalsBibliometricsHumansRisk FactorsImmune Checkpoint InhibitorsBibliometric analysisImmune checkpoint inhibitorsImmune-related adverse eventsPharmacologyTumor immunotherapy

Identifiers

PMID40924107

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.